论文部分内容阅读
胰岛素分泌功能缺陷是推动T2DM发生发展的重要因素。现已发现,许多与T2DM易感性增加相关的基因,大多数与胰岛β细胞功能缺陷有关。在针对胰岛素分泌功能缺陷的治疗策略中,以胰升糖素样肽-1(GLP-1)为基础的药物具有良好的发展前景。
Insulin secretion deficiency is to promote the development of T2DM an important factor. It has been found that many of the genes associated with an increased susceptibility to T2DM are associated with functional deficits of pancreatic beta cells. Glucagon-like peptide-1 (GLP-1) -based drugs have good prospects for development in treatment strategies that are deficient in insulin secretion.